These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 32572567)

  • 1. Effect of nicorandil administration on cardiac burden and cardio-ankle vascular index after coronary intervention.
    Sato S; Takahashi M; Mikamo H; Kawazoe M; Iizuka T; Shimizu K; Noro M; Shirai K
    Heart Vessels; 2020 Dec; 35(12):1664-1671. PubMed ID: 32572567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect on periprocedural myocardial infarction of intra-coronary nicorandil prior to percutaneous coronary intervention in stable and unstable angina.
    Hwang J; Lee HC; Kim BW; Yang MJ; Park JS; Park JH; Lee HW; Oh J; Choi JH; Cha KS; Hong TJ; Song S; Kim SP
    J Cardiol; 2013 Aug; 62(2):77-81. PubMed ID: 23731922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of remote ischemia or nicorandil on myocardial injury following percutaneous coronary intervention in patients with stable coronary artery disease: A randomized controlled trial.
    Miyoshi T; Ejiri K; Kohno K; Nakahama M; Doi M; Munemasa M; Murakami M; Takaishi A; Kawai Y; Sato T; Sato K; Oka T; Takahashi N; Sakuragi S; Mima A; Enko K; Hosogi S; Nanba S; Hirami R; Nakamura K; Ito H;
    Int J Cardiol; 2017 Jun; 236():36-42. PubMed ID: 28214082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nicorandil prevents microvascular dysfunction resulting from PCI in patients with stable angina pectoris: a randomised study.
    Hirohata A; Yamamoto K; Hirose E; Kobayashi Y; Takafuji H; Sano F; Matsumoto K; Ohara M; Yoshioka R; Takinami H; Ohe T
    EuroIntervention; 2014 Jan; 9(9):1050-6. PubMed ID: 24457276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The periprocedural myocardial damage prevention during elective percutaneous coronary intervention as a result of pharmacological preconditioning with an oral form of nicorandil in patients with stable coronary artery disease. Pilot study.
    Gostishchev RV; Soboleva GN; Samko AN; Rogoza AN; Minasyan AA
    Ter Arkh; 2018 Sep; 90(9):53-59. PubMed ID: 30701736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical potential of oral nicorandil to improve myocardial fatty acid metabolism after percutaneous coronary intervention in hemodialysis patients.
    Nishimura M; Okamoto Y; Tokoro T; Sato N; Nishida M; Hashimoto T; Kobayashi H; Yamazaki S; Okino K; Iwamoto N; Takahashi H; Ono T
    Nephron Clin Pract; 2014; 126(1):24-32. PubMed ID: 24434794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardioprotective effects of single oral dose of nicorandil before selective percutaneous coronary intervention.
    Yang J; Zhang J; Cui W; Liu F; Xie R; Yang X; Gu G; Zheng H; Lu J; Yang X; Zhang G; Wang Q; Geng X
    Anatol J Cardiol; 2015 Feb; 15(2):125-31. PubMed ID: 25252296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of nitroglycerin administration on cardio-ankle vascular index.
    Shimizu K; Yamamoto T; Takahashi M; Sato S; Noike H; Shirai K
    Vasc Health Risk Manag; 2016; 12():313-9. PubMed ID: 27536126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of nicorandil treatment for prevention of contrast-induced nephropathy in high-risk patients undergoing cardiac catheterization: A prospective randomized controlled trial.
    Iranirad L; Hejazi SF; Sadeghi MS; Jang SA
    Cardiol J; 2017; 24(5):502-507. PubMed ID: 28281738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of myocardial protection of intracoronary adenosine and nicorandil injection in patients undergoing non-urgent percutaneous coronary intervention: a randomized controlled trial.
    Kim SJ; Kim W; Woo JS; Ha SJ; Kang WY; Hwang SH; Kang DG; Lee SU; Cho SK; Im JS; Kim W
    Int J Cardiol; 2012 Jun; 158(1):88-92. PubMed ID: 21256606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of intravenous nicorandil and preexisting angina pectoris on short- and long-term outcomes in patients with a first ST-segment elevation acute myocardial infarction.
    Ishii H; Ichimiya S; Kanashiro M; Amano T; Ogawa Y; Mitsuhashi H; Sakai S; Uetani T; Murakami R; Naruse K; Murohara T; Matsubara T
    Am J Cardiol; 2007 May; 99(9):1203-7. PubMed ID: 17478142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-analysis of Nicorandil effectiveness on myocardial protection after percutaneous coronary intervention.
    Zhao XT; Zhang CF; Liu QJ
    BMC Cardiovasc Disord; 2019 Jun; 19(1):144. PubMed ID: 31200660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective effect of nicorandil on myocardial injury following percutaneous coronary intervention in older patients with stable coronary artery disease: Secondary analysis of a randomized, controlled trial (RINC).
    Kawakita N; Ejiri K; Miyoshi T; Kohno K; Nakahama M; Doi M; Munemasa M; Murakami M; Nakamura K; Ito H;
    PLoS One; 2018; 13(4):e0194623. PubMed ID: 29659585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective Effect of Remote Ischemic Preconditioning on Myocardial Damage After Percutaneous Coronary Intervention in Stable Angina Patients With Complex Coronary Lesions　- Subanalysis of a Randomized Controlled Trial.
    Ejiri K; Miyoshi T; Kohno K; Nakahama M; Doi M; Munemasa M; Murakami M; Takaishi A; Nakamura K; Ito H;
    Circ J; 2018 Jun; 82(7):1788-1796. PubMed ID: 29669963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Routine Fractional Flow Reserve Measurement After Percutaneous Coronary Intervention.
    van Bommel RJ; Masdjedi K; Diletti R; Lemmert ME; van Zandvoort L; Wilschut J; Zijlstra F; de Jaegere P; Daemen J; van Mieghem NM
    Circ Cardiovasc Interv; 2019 May; 12(5):e007428. PubMed ID: 31018666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of nicorandil infusion on ECG parameters in patients with unstable angina pectoris and percutaneous coronary intervention.
    Wang W; Zhang X; Chen K; Yin L; Gong M; Liu Y; Tse G; Wu L; Li G; Liu T
    Ann Noninvasive Electrocardiol; 2020 Jul; 25(4):e12736. PubMed ID: 31849155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of a novel hyperaemic agent, intracoronary nicorandil, for invasive physiological assessments in the cardiac catheterization laboratory.
    Jang HJ; Koo BK; Lee HS; Park JB; Kim JH; Seo MK; Yang HM; Park KW; Nam CW; Doh JH; Kim HS
    Eur Heart J; 2013 Jul; 34(27):2055-62. PubMed ID: 23396491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preservation of myocardial viability within the risk area by intravenous nicorandil before primary coronary intervention in patients with acute myocardial infarction.
    Umemura S; Nakamura S; Sugiura T; Tsuka Y; Shimojo M; Baden M; Iwasaka T
    Nucl Med Commun; 2008 Nov; 29(11):956-62. PubMed ID: 18836373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuous intravenous infusion of nicorandil for 4 hours before and 24 hours after percutaneous coronary intervention protects against contrast-induced nephropathy in patients with poor renal function.
    Nawa T; Nishigaki K; Kinomura Y; Tanaka T; Yamada Y; Kawasaki M; Minatoguchi S
    Int J Cardiol; 2015 Sep; 195():228-34. PubMed ID: 26048382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in hemodynamic responses between intravenous carperitide and nicorandil in patients with acute heart failure syndromes.
    Hattori H; Minami Y; Mizuno M; Yumino D; Hoshi H; Arashi H; Nuki T; Sashida Y; Higashitani M; Serizawa N; Yamada N; Yamaguchi J; Mori F; Shiga T; Hagiwara N
    Heart Vessels; 2013 May; 28(3):345-51. PubMed ID: 22526380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.